Commenting on the financial results for 2002, Jörg Täubel Managing Director, stated:“It has been an excellent year for Richmond Pharmacology. The level of bookings for trials has continued to grow throughout our first year, and we have doubled our capacity for volunteers accordingly. We are delighted to announce that at the end of our first year of trading we exceeded all expectations in terms of studies completed and by showing profitability.“With good order books and detailed plans to accommodate more trials through the coming year, we are well positioned for another year of profitable growth for Richmond Pharmacology.”

Latest news

Five Years Since a World-First CRISPR Breakthrough at Richmond Pharmacology

December 8, 2025
In November 2020, Richmond Pharmacology made medical history when a patient received the first-ever systemically delivered CRISPR therapy, using lipid nanoparticles to edit genes directly inside the human body.
Read more

Events

JSCPT 2025

5 – 6 December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event